Brought to you by 
Ignyta gets exclusive license to Nerviano's preclinical kinase inhibitors for cancer
18 Mar 2015
Executive Summary
Italian biotech Nerviano Medical Sciences licensed fellow oncology firm Ignyta Inc. (personalized medicine and companion diagnostics) exclusive worldwide development and commercialization rights to two preclinical kinase inhibitors for cancer--RXDX103 and RXDX104.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ignyta gets exclusive license to Nerviano's preclinical kinase inhibitors for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice